Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Holdings Lowered by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC trimmed its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 0.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 130,097 shares of the company’s stock after selling 357 shares during the period. Mutual of America Capital Management LLC owned about 0.34% of Tarsus Pharmaceuticals worth $7,203,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. R Squared Ltd purchased a new stake in Tarsus Pharmaceuticals in the 4th quarter worth about $53,000. Oppenheimer & Co. Inc. purchased a new stake in Tarsus Pharmaceuticals in the 4th quarter worth about $227,000. Baader Bank Aktiengesellschaft purchased a new stake in Tarsus Pharmaceuticals in the 4th quarter worth about $249,000. FMR LLC lifted its stake in Tarsus Pharmaceuticals by 236.6% in the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after acquiring an additional 3,537 shares in the last quarter. Finally, Bleakley Financial Group LLC purchased a new stake in Tarsus Pharmaceuticals in the 4th quarter worth about $323,000. 90.01% of the stock is owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS stock opened at $44.48 on Monday. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $20.08 and a fifty-two week high of $57.28. The stock’s 50-day moving average is $50.97 and its two-hundred day moving average is $43.36. The firm has a market cap of $1.71 billion, a P/E ratio of -11.67 and a beta of 1.01.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The firm had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. Analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on TARS shares. Guggenheim reissued a “buy” rating and issued a $78.00 price objective (up from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. The Goldman Sachs Group increased their price objective on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research note on Friday, November 15th. Oppenheimer increased their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Barclays reduced their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $73.00 target price on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $61.33.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.